On April 29, 2024, Allarity Therapeutics, Inc., a Delaware-based clinical-stage pharmaceutical company, announced that it had regained compliance with the NASDAQ Minimum Bid Price Requirement. The company received formal notice from The Nasdaq Stock Market, LLC confirming that since April 9, 2024, Allarity's common stock had maintained a closing bid price above $1.00 per share for more than ten consecutive trading days. This achievement meets the requirements set forth in Nasdaq's Listing Rule 5550(a)(2), also known as the Bid Price Rule. Thomas Jensen, CEO of Allarity Therapeutics, expressed optimism about the company's compliance with the minimum bid price requirement and the clinical potential of their lead asset, stenoparib, in treating advanced ovarian cancer. The company is focused on the development of stenoparib, utilizing its DRP® companion diagnostic for patient selection in the ongoing phase 2 clinical trial. Allarity Therapeutics is headquartered in the U.S. with a research facility in Denmark and is committed to addressing unmet medical needs in cancer treatment.

On April 29, 2024, Allarity Therapeutics, Inc., a Delaware-based clinical-stage pharmaceutical company, announced that it had regained compliance with the NASDAQ Minimum Bid Price Requirement. The company received formal notice from The Nasdaq Stock Market, LLC confirming that since April 9, 2024, Allarity's common stock had maintained a closing bid price above $1.00 per share for more than ten consecutive trading days. This achievement meets the requirements set forth in Nasdaq's Listing Rule 5550(a)(2), also known as the Bid Price Rule. Thomas Jensen, CEO of Allarity Therapeutics, expressed optimism about the company's compliance with the minimum bid price requirement and the clinical potential of their lead asset, stenoparib, in treating advanced ovarian cancer. The company is focused on the development of stenoparib, utilizing its DRP® companion diagnostic for patient selection in the ongoing phase 2 clinical trial. Allarity Therapeutics is headquartered in the U.S. with a research facility in Denmark and is committed to addressing unmet medical needs in cancer treatment.